Cargando…

Correction: Mutant p53-reactivating compound APR-246 synergizes with asparaginase in inducing growth suppression in acute lymphoblastic leukemia cells

Detalles Bibliográficos
Autores principales:	Ceder, Sophia, Eriksson, Sofi E., Liang, Ying Yu, Cheteh, Emarndeena H., Zhang, Si Min, Fujihara, Kenji M., Bianchi, Julie, Bykov, Vladimir J. N., Abrahmsen, Lars, Clemons, Nicholas J., Nordlund, Pär, Rudd, Sean G., Wiman, Klas G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9349250/ https://www.ncbi.nlm.nih.gov/pubmed/35922423 http://dx.doi.org/10.1038/s41419-022-05130-y

Ejemplares similares

Mutant p53-reactivating compound APR-246 synergizes with asparaginase in inducing growth suppression in acute lymphoblastic leukemia cells
por: Ceder, Sophia, et al.
Publicado: (2021)

A thiol‐bound drug reservoir enhances APR‐246‐induced mutant p53 tumor cell death
por: Ceder, Sophia, et al.
Publicado: (2020)

Targeting of Mutant p53 and the Cellular Redox Balance by APR-246 as a Strategy for Efficient Cancer Therapy
por: Bykov, Vladimir J. N., et al.
Publicado: (2016)

APR-246 reactivates mutant p53 by targeting cysteines 124 and 277
por: Zhang, Qiang, et al.
Publicado: (2018)

Correction: APR-246 reactivates mutant p53 by targeting cysteines 124 and 277
por: Zhang, Qiang, et al.
Publicado: (2019)

Inhibition of the glutaredoxin and thioredoxin systems and ribonucleotide reductase by mutant p53-targeting compound APR-246
por: Haffo, Lena, et al.
Publicado: (2018)

The Mutant p53-Targeting Compound APR-246 Induces ROS-Modulating Genes in Breast Cancer Cells
por: Synnott, Naoise C., et al.
Publicado: (2018)

p53 as a hub in cellular redox regulation and therapeutic target in cancer
por: Eriksson, Sofi E, et al.
Publicado: (2019)

Interleukin-6 derived from cancer-associated fibroblasts attenuates the p53 response to doxorubicin in prostate cancer cells
por: Cheteh, Emarndeena H., et al.
Publicado: (2020)

APR-246/PRIMA-1(MET) inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase
por: Peng, Xiaoxiao, et al.
Publicado: (2017)

APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells
por: Mohell, N, et al.
Publicado: (2015)

Human cancer-associated fibroblasts enhance glutathione levels and antagonize drug-induced prostate cancer cell death
por: Cheteh, Emarndeena H, et al.
Publicado: (2017)

APR-246/PRIMA-1(MET) inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase
por: Peng, X, et al.
Publicado: (2013)

Transketolase regulates sensitivity to APR-246 in p53-null cells independently of oxidative stress modulation
por: Milne, Julia V., et al.
Publicado: (2021)

Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancer
por: Fransson, Åsa, et al.
Publicado: (2016)

APR-246 Enhances Colorectal Cancer Sensitivity to Radiotherapy
por: Xie, Xuqin, et al.
Publicado: (2023)

APR-246 increases tumor antigenicity independent of p53
por: Michels, Judith, et al.
Publicado: (2023)

Pharmacogenetics of asparaginase in acute lymphoblastic leukemia
por: Abaji, Rachid, et al.
Publicado: (2019)

Current Use of Asparaginase in Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
por: Maese, Luke, et al.
Publicado: (2022)

Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes
por: Sallman, David A., et al.
Publicado: (2021)

An open-label phase I dose-finding study of APR-246 in hematological malignancies
por: Deneberg, S, et al.
Publicado: (2016)

Novel compounds that synergize with aminoglycoside G418 or eRF3 degraders for translational readthrough of nonsense mutant TP53 and PTEN
por: Heldin, Angelos, et al.
Publicado: (2023)

APR-246 induces early cell death by ferroptosis in acute myeloid leukemia
por: Birsen, Rudy, et al.
Publicado: (2021)

L-Asparaginase induced thrombosis in acute lymphoblastic leukemia
por: Kulkarni, Ketan P.
Publicado: (2012)

Asparaginase-associated toxicity in children with acute lymphoblastic leukemia
por: Hijiya, Nobuko, et al.
Publicado: (2016)

L-asparaginase in the treatment of patients with acute lymphoblastic leukemia
por: Egler, Rachel A., et al.
Publicado: (2016)

Increased p53 expression induced by APR-246 reprograms tumor-associated macrophages to augment immune checkpoint blockade
por: Ghosh, Arnab, et al.
Publicado: (2022)

Combining APR-246 and HDAC-Inhibitors: A Novel Targeted Treatment Option for Neuroblastoma
por: Müller, Michael, et al.
Publicado: (2021)

Acute pancreatitis following L-asparaginase in acute lymphoblastic leukemia
por: M'harzi, Soulaimane, et al.
Publicado: (2022)

Our Experiences with Asparaginase Activity Measurements in Children with Lymphoblastic Diseases
por: Müller, Judit, et al.
Publicado: (2023)

Pharmacological induction of translational readthrough of nonsense mutations in the retinoblastoma (RB1) gene
por: Palomar-Siles, Mireia, et al.
Publicado: (2023)

Phase Ib study of eprenetapopt (APR-246) in combination with pembrolizumab in patients with advanced or metastatic solid tumors
por: Park, H., et al.
Publicado: (2022)

Variability in functional p53 reactivation by PRIMA-1(Met)/APR-246 in Ewing sarcoma
por: Aryee, D N T, et al.
Publicado: (2013)

Mutant p53 gain of function mediates cancer immune escape that is counteracted by APR-246
por: Zhou, Xiaolei, et al.
Publicado: (2022)

PEG-asparaginase and native Escherichia coli L-asparaginase in acute lymphoblastic leukemia in children and adolescents: a systematic review
por: Medawar, Camile Valle, et al.
Publicado: (2020)

Mechanisms of cell death induced by arginase and asparaginase in precursor B-cell lymphoblasts
por: Métayer, Lucy E., et al.
Publicado: (2018)

PRIMA-1(MET) Inhibits Growth of Mouse Tumors Carrying Mutant p53
por: Zache, Nicole, et al.
Publicado: (2008)

Activity and Toxicity of Intravenous Erwinia Asparaginase Following Allergy to E. coli‐Derived Asparaginase in Children and Adolescents With Acute Lymphoblastic Leukemia
por: Vrooman, Lynda M., et al.
Publicado: (2015)

Asparaginase (native ASNase or pegylated ASNase) in the treatment of acute lymphoblastic leukemia
por: Avramis, Vassilios I, et al.
Publicado: (2006)

L-asparaginase-induced Parotitis in an Elderly Patient with Acute Lymphoblastic Leukemia
por: Saburi, Masuho, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_d3t3pogavaqogbsqbookd0ct27